Home >> Professional Blog

MiMedx Group, Inc. Issued 4 U.S. Patents
for Placenta Tissue Grafts

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, received four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts", with a grant date of January 22, 2013.

The U.S Patent Office has also issued to MiMedx the following three patents with a grant date of February 12, 2013: U.S. Patent Number 8,372,437, "Improved Placental Tissue Grafts"; U.S. Patent Number 8,372,438, "Method For Inhibiting Adhesion Formation Using Improved Placental Grafts"; and U.S. Patent Number 8,372,439, "Method For Treating a Wound Using Improved Placental Tissue Graft". The new patents relate to the Company's placental tissue allografts, including AmnioFix and EpiFix brand allografts.

"These four newly issued patents bring the total to five placental-based U.S. patents that we have recently been issued," said "Pete" Petit, Chairman and CEO. "We are pleased with the pace of review and acceptance of our patent applications preserving the unique intellectual property of our proprietary AmnioFix and EpiFix technologies. At present, we have in excess of 20 additional patent applications that have been filed with the U.S. Patent Office relating to these technologies and our placental tissue allografts. We are encouraged about the prospects of receiving more significant patent issuances resulting from our filings."

The MiMedx allografts produced from the Company's proprietary PURION Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing. The grafts can be utilized right out of the package without a complicated thawing process. These critical qualities of the MiMedx allografts allow hospitals, clinics and surgeons to effectively manage their inventory of allografts.

  Read the full article